Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.58 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27904885 | 0.85 | KDM1A (0.43) | KDM1AKDM1BHTR2CHTR2BSLC6A2 | |
| SCHEMBL179045 | 0.84 | KDM1A (0.63) | KDM1AKDM1BHTR2CHTR2BSLC6A2 | |
| SCHEMBL178948 | 0.81 | KDM1A (0.60) | KDM1AKDM1BHTR2CHTR2BSLC6A2 | |
| SCHEMBL20438980 | 0.81 | HTR2A (0.45) | KDM1AKDM1BHTR2CHTR2BSLC6A2 | |
| SCHEMBL13228876 | 0.80 | KDM1A (0.50) | KDM1AKDM1BHTR2CHTR2BSLC6A2 | |
| SCHEMBL27880809 | 0.79 | HTR1A (0.50) | KDM1AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3333986 | 0.79 | HTR1A (0.50) | KDM1AHTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29698867 | 0.79 | HTR1A (0.50) | KDM1AHTR2CSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4891011 | 0.79 | KDM1A (0.49) | KDM1AKDM1BHTR2CHTR2BSLC6A2 | |
| Hydrochloric Acid SCHEMBL4891014 | 0.79 | KDM1A (0.49) | KDM1AKDM1BHTR2CHTR2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | KDM1A 4195/4885KDM1B 2993/4885HTR2C 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.